1. Home
  2. Research
  3. Research Groups
  4. Molecular Pathology of Cancer Group

Molecular Pathology of Cancer Group

Search for publications

Only original articles, editorials, guidelines.

  • Donato S, Herrera-Martínez AD, Jacome-Gaibor VA, Ruz-Caracuel I, Toledo R, Araujo-Castro M.

    Biomarkers of metastatic disease in pheochromocytoma and paraganglioma.

    Endocrine Connections . 15(8): .

    [doi:10.1530/EC-26-0501]

  • Frutos Díaz-Alejo J, Díaz de la Pinta FJ, Pavía Pascual L, Manso R, Morillo D, Moreno-Delgado M, García-Cosío M, García-Hernández S, García Fernández E, Rebollo-González M, Rodríguez M, Rodríguez Pinilla SM.

    DNMT3A variants are associated with the development of nodal TFH cell lymphoma, angioimmunoblastic-type after solid tumour occurrence.

    BRITISH JOURNAL OF HAEMATOLOGY . 209(2): 740-746.

    [doi:10.1111/bjh.70576]

  • Rescigno P, Taha T, Fita MJ, Matthews D, Fujita K, Lolli C, DI Costanzo F, Juárez A, Ürün Y, Yazgan SC, Li H, Facchini G, Quiroga MN, Sammarco E, Bögemann M, Santini D, Baranseh J, Roviello G, Kopp RM, Fiala O, Büttner T, Carrozza F, Ansari J, Tural D, Conteduca V, Molina-Cerrillo J, Alonso-Gordoa T, Bourlon MT, Palacios GA, Paolieri F, Zgura A, DI Rocco R, Lacerenza LG, Matrana MR, Martignetti A, Massari F, Soares A, Monteiro FS, Bastos DA, Gaughan L, Wenzel M, Mandel P, Banna GL, Santoni M.

    Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

    Minerva Urology and Nephrology . 78(4): 548-559.

    [doi:10.23736/S2724-6051.26.06453-0]

  • Rugo HS, Jhaveri K, Pernas S, Pistilli B, Im SA, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Nowecki Z, Tolaney SM, Zhao K, Atuah K, Verma D, Xu B, Bardia A.

    Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study.

    ESMO Open . 11(8): 108330-108330.

    [doi:10.1016/j.esmoop.2026.108330]

  • Khan F, Polydorides AD, Paulsen JD, Vazzano J, Huber A, Papke D Jr, Sharifai N, Stashek K, Ruz-Caracuel I, Allende D, McHugh K, Shia J, Longacre TA, Dhall D, Makhoul E, Lee MJ, Collins K, Ulbright TM, Zhang ML, Westerhoff M, Gao ZH, Matsukuma K, Choi WT, Kakar S, Chetty R, Nowak K, Serra S, Zhang X, Chen W, Gonzalez RS.

    Enteroblastic and Hepatoid Colorectal Carcinomas are Aggressive Cancers With a Distinctive Immunophenotype, While Clear Cell Carcinoma Appears to Represent Clear Cell Change in Conventional Colorectal Cancer.

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY . 50(8): 883-893.

    [doi:10.1097/PAS.0000000000002555]

  • Grande E, Sibai M, Grases D, Andrada E, Reig O, Escobosa M, Azueta A, Castellano D, Puente J, Martínez de Villarreal J, Font A, Alonso-Gordoa T, Benítez R, Moreno-Oya A, Álvarez-Maestro M, Burgos J, Climent MA, Domínguez M, Galván P, Galante I, García JF, Perez E, García Del Muro X, Guerrero-Ramos F, Marqués M, Maroto P, Paramio JM, Pinto A, Prat A, Malats N, Durán I, Porta-Pardo E, Real FX.

    Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.

    Cell Reports Medicine . 7(7): 102878-102878.

    [doi:10.1016/j.xcrm.2026.102878]

  • Pérez-Ruiz A, Ruiz-Cañas L, Batres S, Ferreras-Martín R, Pinto-Díez C, Yagüe B, Pérez-Morgado MI, Sacristán S, Ruz-Caracuel I, Páez SC, Sanchez-Perez I, González VM, Alcalá S, Martín ME, Sainz B Jr.

    Aptamer-based inhibition of MNK1 reduces pancreatic ductal adenocarcinoma growth by targeting cancer stem cells.

    JOURNAL OF BIOMEDICAL SCIENCE . 33(1): .

    [doi:10.1186/s12929-026-01275-6]

  • Riveiro-Barciela M, Esteban P, Vega-Cano KS, Mateos B, Miranda EL, Jara P, Martín M, Alonso López S, Salcedo M, Forns X, García-Fructuoso I, Martínez-Sáez O, Pinazo-Bandera J, García-Cortés M, Ribelles N, Romanos Nanclares Á, Morchón-Araujo D, Rodríguez CA, Lozano R, Domínguez-Gómez R, Cejuela M, Torres-Sempere J, Ruiz-Cobo JC, Villagrasa A, Zamora E, Buti M, Bellet M.

    Clinical features and management for CDK4/6 inhibitor-DILI.

    JHEP Reports . 8(7): 101873-101873.

    [doi:10.1016/j.jhepr.2026.101873]

  • Martin-Moro F, Alcoceba M, Romero S, Marquet-Palomanes J, Alonso-Castronuño D, Astibia-Mahillo B, Andreu R, Perez-Alonso R, Rodriguez-Martin E, De Ramon C, Solano I, Martin Garcia-Sancho A, Piris-Villaespesa M, Blanco O, Roldan-Santiago E, Garcia-Marco JA, Subira D, Navarro-Bailon A, Garcia-Cosio M, Garcia-Vela JA, Lopez-Jimenez J.

    Phenotypic Characterization of Richter Transformation and De Novo Diffuse Large B-Cell Lymphoma With or Without Monoclonal B-Cell Lymphocytosis.

    MODERN PATHOLOGY . 39(7): 101009-101009.

    [doi:10.1016/j.modpat.2026.101009]

  • Iglesias Álvarez G, Capdevila J, Garcia-Carbonero R, Jimenez-Fonseca P, Benavent M, Vicente MÁ, Llanos M, López C, Alonso V, García-Centeno R, Crespo G, Alonso-Gordoa T, García Paredes B, Sevilla I, Custodio A, Páez D, Segura Á, Gallego J, San Roman M, García-Álvarez A, Alonso Álvarez B, Cacho Lavín JD, Lamarca A, Cano JM, González Florez E, Gómez D, Castaño Á, Carmona-Bayonas A.

    Proximal-To-Distal Gradient and Its Implications in Differentiation and Prognosis in Colorectal Neuroendocrine Neoplasms: The RGETNE-HERACLES Study.

    NEUROENDOCRINOLOGY . 116(6): 1-16. Number of citations: 1

    [doi:10.1159/000552234]

  • Mascaró-Baselga P, Rodellar Sanz JM, Nunes da Silva T, Hernando J, García-Álvarez A, González Merino C, Molina-Cerrillo J, Fernandez-Pombo A, Iglesias-Alvarez G, Ceballos Lenza I, Plana Serrahima M, Bella Cueto MR, Isidro ML, Martinez Trufero J, Marquina G, Martinez N, Crespo G, Jimeno R, Lorenzo I, Ayala de Miguel P, Alcazar V, Martínez-Badal S, Capdevila J, Alonso-Gordoa T.

    Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.

    ONCOLOGIST . 31(7): .

    [doi:10.1093/oncolo/oyag158]

  • López-Robles J, Mitjavila M, Jimenez-Fonseca P, Marín-Melero I, Belló P, Pubul V, Garcia-Burillo A, Hernando J, Llana B, Ardila J, Arbizu J, Valverde R, Velasco M, Castellón M, Alonso-Gordoa T, García-Cañamaque L, Cano JM, Tabuenca MJ, Riesco MC, Custodio AB, Piñeiro A, Balaguer-Muñoz D, Nevares M, Carmona-Bayonas A.

    Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?

    ONCOLOGIST . 31(7): .

    [doi:10.1093/oncolo/oyag231]

  • Peg V, Burgués O, Ruiz I, Carcedo D, García JF, Monzón Naranjo MA, Tonic I, Echeverría T, Segura A, Alfonsín N, Fiaño MC, Pérez-Mies B.

    A Decade of Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer in Spain: A Comprehensive Real-World Data Analysis (2013-2023).

    Clinical Breast Cancer . 26(6): .

    [doi:10.1016/j.clbc.2026.04.009]

  • Barretina-Ginesta MP, Redondo A, Cortés-Salgado A, Madariaga A, Pérez-Mies B, Sancho L, Valls-Masot L, Domínguez M, González-Martín A.

    Assessing platinum response in first-line advanced ovarian cancer: clinical implications and future directions.

    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER . 36(6): 104684-104684. Number of citations: 3

    [doi:10.1016/j.ijgc.2026.104684]

  • Molina-Cerrillo J, Sierra-Ramirez A, López-Aceituno JL, Méndez-Pertuz M, Alonso-Gordoa T, Linnebacher M, Santoni M, Fernandez-Marcos PJ, Grande E.

    A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors.

    DRUGS IN R&D . 26(2): 155-167.

    [doi:10.1007/s40268-026-00544-x]

  • Alonso-Gordoa T, Fernández-Calvo O, García-Carbonero I, Álvarez-Rodríguez S, Sánchez-Escribano R, Anguera G, González-Del-Alba A, Gallardo E, Cacho D, Vidal N, Pinto Á, Perezagua C, Zafra-Poves M, Cassinello J, Rodriguez-Vida A, López-Campos F, Vázquez-Estévez S.

    Patient selection for triplet therapy with darolutamide in metastatic castration-sensitive prostate cancer and patterns of administration: a Spanish multicenter study.

    Clinical & Translational Oncology . 28(6): 2360-2368.

    [doi:10.1007/s12094-025-04174-8]

  • Garrigós L, Ruiz-Borrego M, Pérez-García JM, Guerrero-Zotano A, Cortés-Salgado A, Kuemmel S, Colleoni M, Reboredo-Rendo C, Bermejo B, Blancas I, Gavila J, Fabi A, Morales C, Stradella A, Carañana V, Martínez-de Dueñas E, Albacar C, Ballesteros-Cidras O, Martrat G, Iacobucci S, Boix O, Berenguer-Molins P, Alcalá-López D, Cortés J, Llombart-Cussac A.

    A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.

    ANNALS OF ONCOLOGY . 37(6): 837-848.

    [doi:10.1016/j.annonc.2026.01.013]

  • Sánchez Gómez R, Pérez-Míes B, Palacios J, Moreno Bueno G, Calvo I, Solorzano JL, Neria F, Fernandez-Abad M, González-Martínez S, García-Estevez L.

    Association of Body Mass Index with Tumor-Infiltrating Lymphocytes and Treatment Response in Early HER2-Positive Breast Cancer.

    International Journal of Womens Health . 18: 596039-596039.

    [doi:10.2147/IJWH.S596039]